<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1010346</article-id><article-id pub-id-type="publisher-id">ACM-38155</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201000000_93505853.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  霉酚酸酯对狼疮性肾炎诱导治疗的疗效及安全系统分析的Meta
  Meta-Analysis on the Efficacy and Safety of Mycophenolate Mofete in the Induction Therapy of Lupus Nephritis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>彦超</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邵</surname><given-names>晓珊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>腾飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>邦福</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>田</surname><given-names>琼</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>琼</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>贵阳市妇幼保健院，贵州 贵阳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>10</month><year>2020</year></pub-date><volume>10</volume><issue>10</issue><fpage>2291</fpage><lpage>2301</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：在应用糖皮质激素治疗的基础上，通过与环磷酰胺对比，评价霉酚酸酯对狼疮性肾炎诱导治疗的疗效和安全。方法：通过Cochrance Library、EMBASE、PubMed、中文科技期刊全文数据库(VIP)、中国期刊全文数据库(CNKI)和万方期刊全文数据库查询相关文献，时间均从建库至2020年2月，以纳入及排除标准为依据，获得关于霉酚酸酯对狼疮性肾炎诱导治疗的随机对照试验，汇总疗效指标：临床缓解率(CR + PR)、完全缓解率(CR)和部分缓解率(PR)，安全指标：感染、白细胞减少、胃肠道反应(恶心、呕吐及腹泻)、脱发及月经紊乱。结果：共纳入20篇(中文12篇和英文8篇)，经Meta分析得出：在临床缓解率[OR = 2.37, 95%CI (1.69~3.33), P &lt; 0.00001]及完全缓解率[OR = 1.83, 95%CI (1.38~2.44), P &lt; 0.0001]方面，MMF组均较高于CTX组，且有统计学意义；但两组的部分缓解率[OR = 1.14, 95%CI (0.90~1.44), P = 0.29]，无统计学意义。安全指标：MMF组在感染、脱发、白细胞减少、月经紊乱及恶心、呕吐发生率方面均低于CTX组，结果提示两组差异均具有统计学意义，但在腹泻发生率方面较高。结论：MMF在狼疮性肾炎诱导阶段的治疗效果优于CTX，且不良反应发生率较低。
    Objective: On the basis of glucocorticoid therapy, the efficacy and safety of mycophenolate in induction therapy of lupus nephritis were evaluated by comparing with cyclophosphamide. Methods: Cochrance Library, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), VIP and Wanfang database were screened about mycophenolate mofetil in induction therapy of lupus nephritis, until February 2020. The clinical remission rate (CR + PR), complete remission rate (CR) and partial remission rate (PR) were regarded as curative effect index. Infection, leukopenia, gastrointestinal reactions (nausea, vomiting and diarrhea), alopecia and menstrual disorders were regarded as safety indicators. Results: A total of 20 articles (12 in Chinese and 8 in English) were included. The clinical remission rate [OR = 2.37, 95%CI (1.69 - 3.33), P &lt; 0.00001] and complete remission rate [OR = 1.81, 95%CI (1.43 - 2.28), P &lt; 0.01] in MMF group were higher than those in CTX group, showing statistical significance differences. Safety indicators: The incidence of infection, leukopenia, alopecia, menstrual disorders, nausea and vomiting in MMF group were lower than that in CTX group, indicating statistically significant differences; but being higher than CTX group in the incidence of diarrhea. Conclusion: MMF is better than CTX in the induction therapy of lupus nephritis, and the incidence of adverse reactions is lower. 
  
 
</p></abstract><kwd-group><kwd>狼疮性肾炎，环磷酰胺，霉酚酸酯，随机对照试验，meta分析, Lupus Nephritis</kwd><kwd> Mycophenolate Mofetil</kwd><kwd> Cyclophosphamide</kwd><kwd> Randomized Controlled Trials</kwd><kwd> Meta-Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：在应用糖皮质激素治疗的基础上，通过与环磷酰胺对比，评价霉酚酸酯对狼疮性肾炎诱导治疗的疗效和安全。方法：通过Cochrance Library、EMBASE、PubMed、中文科技期刊全文数据库(VIP)、中国期刊全文数据库(CNKI)和万方期刊全文数据库查询相关文献，时间均从建库至2020年2月，以纳入及排除标准为依据，获得关于霉酚酸酯对狼疮性肾炎诱导治疗的随机对照试验，汇总疗效指标：临床缓解率(CR + PR)、完全缓解率(CR)和部分缓解率(PR)，安全指标：感染、白细胞减少、胃肠道反应(恶心、呕吐及腹泻)、脱发及月经紊乱。结果：共纳入20篇(中文12篇和英文8篇)，经Meta分析得出：在临床缓解率[OR = 2.37, 95%CI (1.69~3.33), P &lt; 0.00001]及完全缓解率[OR = 1.83, 95%CI (1.38~2.44), P &lt; 0.0001]方面，MMF组均较高于CTX组，且有统计学意义；但两组的部分缓解率[OR = 1.14, 95%CI (0.90~1.44), P = 0.29]，无统计学意义。安全指标：MMF组在感染、脱发、白细胞减少、月经紊乱及恶心、呕吐发生率方面均低于CTX组，结果提示两组差异均具有统计学意义，但在腹泻发生率方面较高。结论：MMF在狼疮性肾炎诱导阶段的治疗效果优于CTX，且不良反应发生率较低。</p></sec><sec id="s2"><title>关键词</title><p>狼疮性肾炎，环磷酰胺，霉酚酸酯，随机对照试验，meta分析</p></sec><sec id="s3"><title>Meta-Analysis on the Efficacy and Safety of Mycophenolate Mofete in the Induction Therapy of Lupus Nephritis</title><p>Yanchao Li, Xiaoshan Shao, Tengfei Zhang, Bangfu Xiao, Qiong Tian, Qiong Wu</p><p>Guiyang Maternal and Child Health Care Hospital, Guiyang Guizhou</p><p><img src="//html.hanspub.org/file/13-1571576x4_hanspub.png" /></p><p>Received: Sep. 29<sup>th</sup>, 2020; accepted: Oct. 14<sup>th</sup>, 2020; published: Oct. 21<sup>st</sup>, 2020</p><p><img src="//html.hanspub.org/file/13-1571576x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: On the basis of glucocorticoid therapy, the efficacy and safety of mycophenolate in induction therapy of lupus nephritis were evaluated by comparing with cyclophosphamide. Methods: Cochrance Library, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), VIP and Wanfang database were screened about mycophenolate mofetil in induction therapy of lupus nephritis, until February 2020. The clinical remission rate (CR + PR), complete remission rate (CR) and partial remission rate (PR) were regarded as curative effect index. Infection, leukopenia, gastrointestinal reactions (nausea, vomiting and diarrhea), alopecia and menstrual disorders were regarded as safety indicators. Results: A total of 20 articles (12 in Chinese and 8 in English) were included. The clinical remission rate [OR = 2.37, 95%CI (1.69 - 3.33), P &lt; 0.00001] and complete remission rate [OR = 1.81, 95%CI (1.43 - 2.28), P &lt; 0.01] in MMF group were higher than those in CTX group, showing statistical significance differences. Safety indicators: The incidence of infection, leukopenia, alopecia, menstrual disorders, nausea and vomiting in MMF group were lower than that in CTX group, indicating statistically significant differences; but being higher than CTX group in the incidence of diarrhea. Conclusion: MMF is better than CTX in the induction therapy of lupus nephritis, and the incidence of adverse reactions is lower.</p><p>Keywords:Lupus Nephritis, Mycophenolate Mofetil, Cyclophosphamide, Randomized Controlled Trials, Meta-Analysis</p><disp-formula id="hanspub.38155-formula3"><graphic xlink:href="//html.hanspub.org/file/13-1571576x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/13-1571576x7_hanspub.png" /> <img src="//html.hanspub.org/file/13-1571576x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>系统性红斑狼疮是一种常见的自身免疫性疾病，以多系统受累为主要表现和血清中产生自身抗体为特征。女性发病率较高，而药物的安全指标(月经紊乱及脱发尤为严重)对女性的影响也较明显。由于体内外各种因素导致患者的自身抗原被暴露于内环境中，因而被免疫系统当作外来抗原，引起T、B细胞大量增殖与活化，并分泌抗体 [<xref ref-type="bibr" rid="hanspub.38155-ref1">1</xref>]。在系统性红斑狼疮确诊的最初5年内，40%患者伴有活动性狼疮性肾炎；在其确诊的最初10年内，约5%~20%的患者发展为尿毒症期，因此狼疮性肾炎具有高发病率及致死率的倾向 [<xref ref-type="bibr" rid="hanspub.38155-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref4">4</xref>]。以前通常选择环磷酰胺 + 激素联合治疗的方案，因其为细胞毒类药物，可以作用于增殖细胞特定的周期，因而在短时间内疗效并不理想；又因其对作用细胞的选择性差及个体差异的缘故，部分患者在疗程中会出现诸多不良反应，进而导致患儿耐受性下降，无法进行足够的疗程。霉酚酸酯作为一种新型免疫抑制剂，其活性代谢产物霉酚酸，能够高选择性地抑制患者机体内T、B细胞的增殖情况及其功能，使得免疫复合物在肾脏中的表达水平下调及积蓄减少，这样从根源上有效减少自身免疫复合物对肾脏的损伤，因此也较少了不良反应。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 检索策略</title><p>以英文关键词“lupus nephritis, lupus erythematosus and LN; cyclophosphamide and CTX; mycophenolicacid, mycophenolate mofetiland MMF; randomized controlled trials”查找Cochrance Library、PubMed、EMBASE (截止到2020年02月)，检索方式：关键词 + 自由词；以中文关键词“吗替麦考酚酯或骁悉或霉酚酸酯、随机对照试验、狼疮性肾炎或系统性红斑狼疮或狼疮肾炎、环磷酰胺”查找VIP、CNKI和万方期刊全文数据库(截止到2020年02月)。</p></sec><sec id="s6_2"><title>2.2. 纳入标准</title><sec id="s6_2_1"><title>2.2.1. 研究设计</title><p>纳入的研究均为前瞻性随机对照试验(RCT)。</p></sec><sec id="s6_2_2"><title>2.2.2. 研究对象</title><p>纳入患者的诊断必须符合美国风湿病协会系统性红斑狼疮的诊断标准 [<xref ref-type="bibr" rid="hanspub.38155-ref5">5</xref>]，并且肾脏病理活组织检查检确诊为III~V型及其2种混合，患者年龄不限。</p></sec><sec id="s6_2_3"><title>2.2.3. 干预措施</title><p>诱导治疗：CTX组为激素 + CTX (静脉滴注)；MMF组为激素 + MMF (口服)。</p></sec><sec id="s6_2_4"><title>2.2.4. 疗程</title><p>至少为6个月。</p></sec></sec><sec id="s6_3"><title>2.3. 排除标准</title><p>1) 非随机对照试验、回顾性研究及动物试验。</p><p>2) 继发于肾淀粉样变、糖尿病、细菌及病毒感染引起的肾病。</p><p>3) 狼疮性肾炎维持阶段的治疗病理活检非III~V型及其混合。</p><p>4) 联合应用免疫抑制剂者。</p></sec><sec id="s6_4"><title>2.4. 纳入文献质量评价准则</title><p>按照国际通用的Jadad评分标准对纳入的文献进行质量评价 [<xref ref-type="bibr" rid="hanspub.38155-ref6">6</xref>]。其具体内容包括：具体随机方法；分配过程是否隐藏；盲法及盲法方案；试验开始基线是否相似；退出与失访(包含具体的人数及原因)。基本满足上述情况，发生各种偏倚的风险最小，评为A级；大部分满足上述情况，发生偏倚的风险为中度，评为B级；仅小部分满足上述情况，发生各种偏倚的可能性最大，评为C级。</p></sec><sec id="s6_5"><title>2.5. 资料处理过程</title><p>由2名评价员对所选择的文献分别进行独立质量评价，依据标题和摘要粗略地剔除无关的文献；然后获取全文，仔细推敲并对满意的文献加以标记，并提取相关数据，随后交叉核对彼此统计的信息, 存有争议的地方通过讨论或向第3位研究者寻求帮助。</p></sec><sec id="s6_6"><title>2.6. 选择的统计学方法</title><p>通过Cochrane协作网发布的RevMan5.1版本进行Meta分析，计数资料采用比值比(OR)及其95%CI表示。对纳入的研究进行临床异质性和方法学异质性分析，若有需要给予临床异质性和方法学异质性的原则进行亚组分析，若各研究间(P ≥ 0.1)，则选择固定效应模型；若研究间(P &lt; 0.1)且证实不是来源于临床异质性，则可采用随机效应模型；如果研究间存在异质性过大或者来源于临床的异质性，只进行描述性分析而不进行统计量的合并。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 文献检索结果</title><p>在上述数据库输入对应关键词后共发现相关RCT文献350篇(英文247篇和中文103篇)。去除重复文献43篇，经过阅读标题及摘要、获取全文及提取相关数据，再依据纳入及排除标准，进行筛查，共有20篇(如表1所示) [<xref ref-type="bibr" rid="hanspub.38155-ref7">7</xref>] - [<xref ref-type="bibr" rid="hanspub.38155-ref26">26</xref>] 临床研究符合要求(包括12篇中文及8篇英文)，纳入患者为1622例。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic information of the included literatur</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >作者</th><th align="center" valign="middle"  rowspan="2"  >总病 例数</th><th align="center" valign="middle"  rowspan="2"  >平均年龄</th><th align="center" valign="middle"  rowspan="2"  >性别 (女/男)</th><th align="center" valign="middle"  rowspan="2"  >肾脏病理分型</th><th align="center" valign="middle"  rowspan="2"  >Jadad评分</th><th align="center" valign="middle"  colspan="2"  >治疗方案</th><th align="center" valign="middle"  rowspan="2"  >疗程</th></tr></thead><tr><td align="center" valign="middle" >MMF组</td><td align="center" valign="middle" >CTX</td></tr><tr><td align="center" valign="middle" >方艳玲 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref7">7</xref>]</td><td align="center" valign="middle" >58</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >19/39</td><td align="center" valign="middle" >III型、IV型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >第一周1 g/d，第二周以后2 g/d</td><td align="center" valign="middle" >每月0.5~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Sedhain et al. [<xref ref-type="bibr" rid="hanspub.38155-ref8">8</xref>]</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >37/5</td><td align="center" valign="middle" >III型、IV型、 V型及混合</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >体重 &gt; 50 kg，1.5 g/d，bid；体重 &lt; 50 kg，1.0 g/d，bid，30 d后逐渐逐渐加量至1.5 g/天</td><td align="center" valign="middle" >每月0.5~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >张世杰 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref10">10</xref>]</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >68/10</td><td align="center" valign="middle" >III型、IV型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >1.5 g/d，bid，在3~6月根据病情减至0.5~1.0 g/d</td><td align="center" valign="middle" >1 g/d，持续2天，1次/月</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >秦测 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref12">12</xref>]</td><td align="center" valign="middle" >88</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >60/28</td><td align="center" valign="middle" >III型 + IV型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >1.5~2.0 g/d，bid或tid</td><td align="center" valign="middle" >0.6~0.8 mg/(Kg * d)，30天后根据病情减量，减至10 mg/天</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >魏欣 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref11">11</xref>]</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >65/9</td><td align="center" valign="middle" >IV型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >1.5~2.0 g/d，bid</td><td align="center" valign="middle" >每月0.5~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >苗小勇 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref9">9</xref>]</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >63/33</td><td align="center" valign="middle" >IV型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >1.0~1.5 g/d，bid；3个月后改为0.5 g/d，bid</td><td align="center" valign="middle" >每月0.75~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >~</td></tr><tr><td align="center" valign="middle" >Rathi et al. [<xref ref-type="bibr" rid="hanspub.38155-ref13">13</xref>]</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >92/8</td><td align="center" valign="middle" >III型、IV型、 V型及混合</td><td align="center" valign="middle" >B</td><td align="center" valign="middle" >1.5~3.0 g/d</td><td align="center" valign="middle" >每月0.75~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >吕先佑 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref15">15</xref>]</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >66/0</td><td align="center" valign="middle" >IV型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >1.5 g/d，bid，随后根据病情减至0.5 g/d</td><td align="center" valign="middle" >1 g/d，持续2天，1次/月</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >张和平 et al.</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >40/10</td><td align="center" valign="middle" >IV型 + Ⅴ型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >1.5 g/d，bid</td><td align="center" valign="middle" >每月0.75~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >许圣淳 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref16">16</xref>]</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >71/9</td><td align="center" valign="middle" >IV型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >1.5~2.0 g/d，bid或tid</td><td align="center" valign="middle" >每月0.5~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >刘春雅 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref17">17</xref>]</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >70/9</td><td align="center" valign="middle" >III型、IV型、 V型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >体重 &lt; 50 kg，1.5 g/d，bid；体重 &gt; 50 kg，2.0 g/d，bid，6个月后逐渐减量</td><td align="center" valign="middle" >1 g/d，1次/月，共6个月；1 g/d，3月1次，共18个月</td><td align="center" valign="middle" >24</td></tr><tr><td align="center" valign="middle" >彭少华 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref18">18</xref>]</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >56/15</td><td align="center" valign="middle" >III型、IV型</td><td align="center" valign="middle" >B</td><td align="center" valign="middle" >第一周1 g/d，第二周以后2 g/d，bid</td><td align="center" valign="middle" >每月0.5~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Li et al. [<xref ref-type="bibr" rid="hanspub.38155-ref19">19</xref>]</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >35/5</td><td align="center" valign="middle" >III型、IV型、 V型及混合</td><td align="center" valign="middle" >B</td><td align="center" valign="middle" >体重 &lt; 55 kg，1.5 g/d，bid；体重 &gt; 55 kg，2.0 g/d，bid</td><td align="center" valign="middle" >每月0.5~0.75 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >张延 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref20">20</xref>]</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >35/0</td><td align="center" valign="middle" >IV型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >体重 &lt; 55 kg，1.0 g/d，bid；体重 &gt; 55 kg，1.5 g/d，bid；6个月后减至0.5~0.75 g/d</td><td align="center" valign="middle" >每月0.75~1.0 g/m<sup>2</sup>，6个月后，改为每3月0.75~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >12</td></tr><tr><td align="center" valign="middle" >和青松 et al. [<xref ref-type="bibr" rid="hanspub.38155-ref21">21</xref>]</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >53/7</td><td align="center" valign="middle" >III型、IV型、 V型</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >初始1.5~2.0 g/d，bid，每3~6个月减0.25~0.5 g/d，达到0.5~0.75 g/d维持</td><td align="center" valign="middle" >0.75 g/m<sup>2</sup>，根据病情调整为0.5~1.0 g/m<sup>2</sup>，每月1次</td><td align="center" valign="middle" >9</td></tr><tr><td align="center" valign="middle" >El-shafey et al. [<xref ref-type="bibr" rid="hanspub.38155-ref22">22</xref>]</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >45/2</td><td align="center" valign="middle" >III型、IV型</td><td align="center" valign="middle" >B</td><td align="center" valign="middle" >1.0 g/d，bid</td><td align="center" valign="middle" >每月0.5~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Appel et al. [<xref ref-type="bibr" rid="hanspub.38155-ref23">23</xref>]</td><td align="center" valign="middle" >370</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >313/57</td><td align="center" valign="middle" >III型、IV型、 V型及混合</td><td align="center" valign="middle" >B</td><td align="center" valign="middle" >2.6 g/d，bid</td><td align="center" valign="middle" >每月0.75 g/m<sup>2</sup></td><td align="center" valign="middle" >12</td></tr><tr><td align="center" valign="middle" >Wang et al. [<xref ref-type="bibr" rid="hanspub.38155-ref24">24</xref>]</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >IV型</td><td align="center" valign="middle" >B</td><td align="center" valign="middle" >0.75~1.0 g/d，bid</td><td align="center" valign="middle" >每月0.75~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Ong et al. [<xref ref-type="bibr" rid="hanspub.38155-ref25">25</xref>]</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >37/7</td><td align="center" valign="middle" >III型、IV型</td><td align="center" valign="middle" >B</td><td align="center" valign="middle" >1.0 g/d，bid</td><td align="center" valign="middle" >每月0.75~1.0 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Ginzler et al. [<xref ref-type="bibr" rid="hanspub.38155-ref26">26</xref>]</td><td align="center" valign="middle" >140</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >126/14</td><td align="center" valign="middle" >III型、IV型、 V型及混合</td><td align="center" valign="middle" >B</td><td align="center" valign="middle" >第一周0.5 g/d，bid;第二周0.75 g/d，bid；白细胞不低于3.0 &#215; 10<sup>9</sup>/L，1.0 g/d，bid</td><td align="center" valign="middle" >每月0.5~0.75 g/m<sup>2</sup></td><td align="center" valign="middle" >6</td></tr></tbody></table></table-wrap><p>表1. 纳入文献的基本信息</p></sec><sec id="s7_2"><title>3.2. 文献质量</title><p>20篇文献均提及随机对照试验，但仅有5篇文献 [<xref ref-type="bibr" rid="hanspub.38155-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref25">25</xref>] 描述了随机化方法(随机数字表法和中央随机)；1篇文献 [<xref ref-type="bibr" rid="hanspub.38155-ref24">24</xref>] 记录了分配隐藏方式(信封)；2篇文献 [<xref ref-type="bibr" rid="hanspub.38155-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref25">25</xref>] 采取了盲法(单盲)；10篇 [<xref ref-type="bibr" rid="hanspub.38155-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref21">21</xref>] - [<xref ref-type="bibr" rid="hanspub.38155-ref26">26</xref>] 报道了失访及退出(具体人数及原因)。9篇文献 [<xref ref-type="bibr" rid="hanspub.38155-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref26">26</xref>] 认为是B级，11篇文献 [<xref ref-type="bibr" rid="hanspub.38155-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.38155-ref21">21</xref>] 认为是C级。</p></sec><sec id="s7_3"><title>3.3. 疗效分析</title><p>在这20篇研究中仅有1篇未提及PR，因此未能将其部分缓解率及临床缓解率进行汇总分析。临床缓解率有轻度异质性(P = 0.09, I2 = 0.32)，随机效应模型，两组差异具有统计学意义[OR = 2.37, 95%CI: 1.69~3.33, P &lt; 0.00001]，如图1。完全缓解率各组间无异质性，选择固定效应模型(OR = 1.83, 95%CI: 1.38~2.44, P &lt; 0.0001)，差异具有统计学意义，如图2；部分缓解率各组间无异质性，选择固定效应模型(OR = 1.14, 95%CI: 0.90~1.44, P = 0.29)，差异无统计学意义，如图3。</p></sec><sec id="s7_4"><title>3.4. 安全指标</title><p>所纳入的研究中各项安全指标在组间均无异质性，均选择固定效应模型，两组差异均有统计学意义，包括感染：(OR = 0.67, 95%CI: 0.5~0.9, P = 0.007)，如图4、恶心、呕吐：(OR = 0.27, 95%CI (0.17~0.43), P &lt; 0.01)，如图5、腹泻：(OR = 2.72, 95%CI: 1.82~4.14, P &lt; 0.01)，如图6、白细胞减少：(OR = 0.48, 95%CI: 0.28~0.82, P = 0.007)，如图7、月经紊乱：(OR = 0.26, 95%CI: 0.12~0.54, P = 0.0003)，如图8、脱发(OR = 0.09, 95%CI: 0.03~0.32, P = 0.0002)，如图9。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>环磷酰胺与糖皮质激素联合是治疗LN的经典方案，可将临床存活率明显提高，又因其不良反应较</p><p>图1. MMF对比CTX关于治疗狼疮性肾炎临床缓解率</p><p>图2. MMF对比CTX关于治疗狼疮性肾炎完全缓解率</p><p>图3. MMF对比CTX关于治疗狼疮性肾炎部分缓解率</p><p>图4. MMF对比CTX关于治疗狼疮性肾炎感染发生率</p><p>图5. MMF对比CTX关于治疗狼疮性肾炎恶心、呕吐发生率</p><p>图6. MMF对比CTX关于治疗狼疮性肾炎腹泻发生率</p><p>图7. MMF对比CTX关于治疗狼疮性肾炎白细胞减少发生率</p><p>图8. MMF对比CTX关于治疗狼疮性肾炎月经紊乱发生率</p><p>图9. MMF对比CTX关于治疗狼疮性肾炎脱发发生</p><p>多，许多患者出现不耐受的情况。而霉酚酸酯是一种相对特异的免疫抑制剂，不良反应相对较少。近来有不少相关随机对照文献，因其选择要求不同，造成结论也不完全一致。2010年Kamanamool等 [<xref ref-type="bibr" rid="hanspub.38155-ref27">27</xref>]、2012年Liu等 [<xref ref-type="bibr" rid="hanspub.38155-ref28">28</xref>] 及2014年张任等 [<xref ref-type="bibr" rid="hanspub.38155-ref29">29</xref>] 发表的Meta分析均只纳入英文文献，且样本量偏小；2013年陈晓青等 [<xref ref-type="bibr" rid="hanspub.38155-ref30">30</xref>] 发表的Meta分析虽然纳入11篇文献，但纳入的英文文献不完全，并且纳入的中文文献质量欠佳。针对上述情况，本文严格按照纳入和排除标准对文献进行筛查，纳入的文献综合考虑语种不限，选取高质量的文章，尽量减少各种偏倚的发生。</p><p>从疗效方面考虑，霉酚酸酯组可显著提高狼疮性肾炎在诱导治疗阶段的完全缓解率、总缓解率, 且具有统计学意义；但在部分缓解率方面两者差异无统计学意义，这与Kamanamool et al. [<xref ref-type="bibr" rid="hanspub.38155-ref27">27</xref>] 研究结果类似。将本文与已发表的相关研究结合，提示：在以糖皮质激素为基础治疗的情况下，MMF在狼疮性肾炎的诱导治疗的效果优于或者等于CTX的作用。</p><p>从安全指标考虑，霉酚酸酯可明显降低感染、脱发、月经紊乱、白细胞减少及恶心、呕吐方面的发生率。但在腹泻方面则相反，表现出霉酚酸酯出现这种情况的可能性较大，与Li et al. [<xref ref-type="bibr" rid="hanspub.38155-ref31">31</xref>] 的结论一致。由于环磷酰胺选择性不强，它可以广泛地作用于细胞，因此可能出现较多的不良事件，对于女性的影响更加严重，尤其是育龄期的患者(狼疮性肾炎本身对育龄期女性产生影响较大，但应用药物给予治疗，则会对胎儿造成致畸的风险 [<xref ref-type="bibr" rid="hanspub.38155-ref32">32</xref>] )。因此，可以得出在治疗狼疮性肾炎的过程中，患者对霉酚酸酯的耐受性相对较好。有些文献仅仅阐述了胃肠道反应发生率，并未将恶心、呕吐与腹泻分别进行考虑，则产生了不一致的结论。</p></sec><sec id="s9"><title>5. 结论</title><p>MMF在狼疮性肾炎诱导阶段的治疗效果优于CTX，且不良反应发生率相对较低。本研究纳入的RCT文献相对较全，仍有不足：含有的中文文献质量偏低；各个研究的病理类型并未统一；仅有1篇文献纳入的样本量偏少；各文献对缓解的定义及关注的目标也稍有差别。综上所述，仍需要大样本、多中心研究、高质量文献、疗程更长的随机对照试验。</p><p>检索方式：#1 lupus nephritis</p><p>#2 Lupus Glomerulonephritis OR Nephritis, Lupus OR Lupus Nephritides OR Nephritides, Lupus OR Glomerulonephritis, Lupus OR Glomerulonephritides, Lupus OR Lupus Glomerulonephritides</p><p>#3 Lupus Glomerulonephritis</p><p>#4 Nephritis, Lupus OR Lupus Nephritides OR Nephritides, Lupus OR Glomerulonephritis, Lupus OR Glomerulonephritides, Lupus OR Lupus Glomerulonephritides</p><p>#5 #1 or #2 or #3 or #4</p><p>#6 cyclophosphamide</p><p>#7 B-518 ORB 518 OR B518 OR Cyclophosphamide Anhydrous OR Cyclophosphamide, (R)-Isomer OR Cyclophosphamide, (S)-Isomer OR Cytophosphane OR Cyclophosphamide Monohydrate OR Cytophosphan OR Cytoxan OR Endoxan OR Neosar OR NSC-26271 OR NSC 26271 OR NSC26271 OR Procytox OR (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate OR Cyclophosphane</p><p>#8 #6 or #7</p><p>#9 mycophenolatemofetil</p><p>#10 Mycophenolate Mofetil OR Mofetil, Mycophenolate OR Mycophenolic Acid Morpholinoethyl Ester OR Cellcept OR Mycophenolate Sodium OR Sodium Mycophenolate OR Mycophenolate, Sodium OR Myfortic OR Mycophenolate Mofetil Hydrochloride OR Mofetil Hydrochloride, Mycophenolate OR RS 61443 OR RS-61443 OR RS61443</p><p>#11 #9 or #10</p><p>#12 randomized controlled trials</p><p>#13 Clinical Trials, Randomized OR Trials, Randomized Clinical OR Controlled Clinical Trials, Randomized</p><p>#14 #12 or #13</p><p>#15 #5 and #8 and #11 and #14。</p></sec><sec id="s10"><title>文章引用</title><p>李彦超,邵晓珊,张腾飞,肖邦福,田 琼,吴 琼. 霉酚酸酯对狼疮性肾炎诱导治疗的疗效及安全系统分析的MetaMeta-Analysis on the Efficacy and Safety of Mycophenolate Mofete in the Induction Therapy of Lupus Nephritis[J]. 临床医学进展, 2020, 10(10): 2291-2301. https://doi.org/10.12677/ACM.2020.1010346</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38155-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">刘瑞华, 余学清. 狼疮肾炎发病机制的研究进展[J]. 中华肾脏病杂志, 2019, 35(12): 950-953.</mixed-citation></ref><ref id="hanspub.38155-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Almaani, S., Meara, A. and Rovin, B.H. (2017) Update on Lupus Nephritis. Clinical Journal of the American Society of Nephrology, 12, 825-835. &lt;br&gt;https://doi.org/10.2215/CJN.05780616</mixed-citation></ref><ref id="hanspub.38155-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Anders, H.J., Saxena, R., Zhao, M.H., et al. (2020) Lupus Nephritis. Nature Reviews Disease Primers, 6, 25.  
&lt;br&gt;https://doi.org/10.1038/s41572-019-0141-9</mixed-citation></ref><ref id="hanspub.38155-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hoover, P.J. and Costenbader, K.H. (2016) Insights into the Epidemiology and Management of Lupus Nephritis from the US Rheumatologist’s Perspective. Kidney International, 90, 487-492. &lt;br&gt;https://doi.org/10.1016/j.kint.2016.03.042</mixed-citation></ref><ref id="hanspub.38155-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hochberg, M.C. (1997) Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis &amp; Rheumatology, 40, 1725. &lt;br&gt;https://doi.org/10.1002/art.1780400928</mixed-citation></ref><ref id="hanspub.38155-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Jadad, A.R., Moore, R.A., Carroll, D., et al. (1996) Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Controlled Clinical Trials, 17, 1-12. &lt;br&gt;https://doi.org/10.1016/0197-2456(95)00134-4</mixed-citation></ref><ref id="hanspub.38155-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">方艳玲. 霉酚酸酯与环磷酰胺治疗狼疮性肾炎效果对比[J]. 临床合理用药杂志, 2018, 11(31): 68-69.</mixed-citation></ref><ref id="hanspub.38155-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sedhain, A., Hada, R., Agrawal, R.K., et al. (2018) Low Dose Mycophenolate Mofetil versus Cyclophosphamide in the Induction Therapy of Lupus Nephritis in Nepalese Population: A Randomized Control Trial. BMC Nephrology, 19, Article No. 175. &lt;br&gt;https://doi.org/10.1186/s12882-018-0973-7</mixed-citation></ref><ref id="hanspub.38155-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">苗小勇. 霉酚酸酯与间断环磷酰胺静脉冲击疗法治疗弥漫增生型狼疮性肾炎的效果比较[J]. 河南医学研究, 2017, 26(4): 697-698.</mixed-citation></ref><ref id="hanspub.38155-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">张世杰. 霉酚酸酯与环磷酰胺分别联合激素治疗狼疮性肾炎比较[J]. 中外医疗, 2016, 35(12): 27-29.</mixed-citation></ref><ref id="hanspub.38155-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">魏欣. 弥漫增生性狼疮性肾炎应用吗替麦考酚酯实施诱导治疗的效果[J]. 医学新知杂志, 2016, 26(2): 116-118.</mixed-citation></ref><ref id="hanspub.38155-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">秦测. 霉酚酸酯和环磷酰胺治疗Ⅳ型伴Ⅴ型狼疮性肾炎的临床疗效比较[J]. 中国医药科学, 2016, 6(3): 92-94.</mixed-citation></ref><ref id="hanspub.38155-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Rathi, M., Goyal, A., Jaryal, A., et al. (2016) Comparison of Low-Dose Intravenous Cyclophosphamide with Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis. Kidney International, 89, 235-242.  
&lt;br&gt;https://doi.org/10.1038/ki.2015.318</mixed-citation></ref><ref id="hanspub.38155-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">张和平, 林玲, 樊雷, 等. 探讨霉酚酸酯与环磷酰胺治疗IV型伴V型狼疮性肾炎的疗效对比[J]. 中国医药指南, 2015, 13(13): 78.</mixed-citation></ref><ref id="hanspub.38155-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">吕先佑. 霉酚酸酯对比CTX方案治疗狼疮性肾炎Ⅳ型患者的干预效果评价[J]. 医学信息, 2015, 28(50): 194.</mixed-citation></ref><ref id="hanspub.38155-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">许圣淳, 刘正钊, 章海涛, 等. 吗替麦考酚酯诱导治疗弥漫增生性狼疮性肾炎的临床疗效[J]. 肾脏病与透析肾移植杂志, 2014, 23(6): 512-516+506.</mixed-citation></ref><ref id="hanspub.38155-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">刘春雅, 姜毅, 汪丽.霉酚酸酯与环磷酰胺治疗难治性狼疮性肾炎的疗效比较[J]. 中国现代医生, 2014, 51(31): 48-50.</mixed-citation></ref><ref id="hanspub.38155-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">彭少华, 陈婷, 陈勇. 霉酚酸酯与环磷酰胺治疗狼疮性肾炎的疗效及安全性对比研究[J]. 中国全科医学, 2012, 15(15): 1722-1724.</mixed-citation></ref><ref id="hanspub.38155-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Ren, H., Zhang, Q., et al. (2012) Mycophenolate Mofetil or Tacrolimus Compared with Intravenous Cyclophosphamide in the Induction Treatment for Active Lupus Nephritis. Nephrology Dialysis Transplantation, 27, 1467-1472.  
&lt;br&gt;https://doi.org/10.1093/ndt/gfr484</mixed-citation></ref><ref id="hanspub.38155-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">张延. 霉酚酸酯与环磷酰胺治疗IV型狼疮性肾炎的疗效比较[J]. 现代预防医学, 2011, 38(18): 3842-3844.</mixed-citation></ref><ref id="hanspub.38155-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">和青松, 张连云, 马海军, 等. 吗替麦考酚酯和环磷酰胺治疗狼疮性肾炎的对照研究[J]. 中国医疗前沿(下半月), 2010, 5(9): 3-4, 58.</mixed-citation></ref><ref id="hanspub.38155-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">El-Shafey, E.M., Abdou, S.H. and Shareef, M.M. (2010) Is Mycophenolate Mofetil Superior to Pulse Intravenous Cyclophosphamide for Induction Therapy of Proliferative Lupus Nephritis in Egyptian Patients? Clinical and Experimental Nephrology, 14, 214-221. &lt;br&gt;https://doi.org/10.1007/s10157-010-0270-7</mixed-citation></ref><ref id="hanspub.38155-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Appel, G.B., Contreras, G., Dooley, M.A., et al. (2009) Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. Journal of the American Society of Nephrology, 20, 1103-1112.  
&lt;br&gt;https://doi.org/10.1681/ASN.2008101028</mixed-citation></ref><ref id="hanspub.38155-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Hu, W., Xie, H., et al. (2007) Induction Therapies for Class IV Lupus Nephritis with Non-Inflammatory Necrotizing Vasculopathy: Mycophenolate Mofetil or Intravenous Cyclophosphamide. Lupus, 16, 707-712.  
&lt;br&gt;https://doi.org/10.1177/0961203307081340</mixed-citation></ref><ref id="hanspub.38155-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ong, L.M., Hooi, L.S., Lim, T.O., et al, J. (2005) Randomized Controlled Trial of Pulse Intravenous Cyclophosphamide versus Mycophenolate Mofetil in the Induction Therapy of Proliferative Lupus Nephritis. Nephrology (Carlton), 10, 504-510. &lt;br&gt;https://doi.org/10.1111/j.1440-1797.2005.00444.x</mixed-citation></ref><ref id="hanspub.38155-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Ginzler, E.M., Dooley, M.A., Aranow, C., et al. (2005) Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. The New England Journal of Medicine, 353, 2219-2228. &lt;br&gt;https://doi.org/10.1056/NEJMoa043731</mixed-citation></ref><ref id="hanspub.38155-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Kamanamool, N., McEvoy, M., Attia, J., et al. (2010) Efficacy and Adverse Events of Mycophenolate Mofetil versus Cyclophosphamide for Induction Therapy of Lupus Nephritis: Systematic Review and meta-Analysis. Medicine (Baltimore), 89, 227-235. &lt;br&gt;https://doi.org/10.1097/MD.0b013e3181e93d00</mixed-citation></ref><ref id="hanspub.38155-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L.L., Jiang, Y., Wang, L.N., et al. (2012) Efficacy and Safety of Mycophenolate Mofetil versus Cyclophosphamide for Induction Therapy of Lupus Nephritis: A Meta-Analysis of Randomized Controlled Trials. Drugs, 72, 1521-1533. &lt;br&gt;https://doi.org/10.2165/11635030-000000000-00000</mixed-citation></ref><ref id="hanspub.38155-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">张任, 杨一菲. 吗替麦考酚酯诱导治疗狼疮性肾炎的Meta分析[J]. 武汉大学学报(医学版), 2015, 36(5): 831-838.</mixed-citation></ref><ref id="hanspub.38155-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">陈晓青, 苑克晶, 王婉宁, 等. 霉酚酸酯和环磷酰胺诱导治疗狼疮性肾炎的系统评价[J]. 中国老年学杂志, 2015(2): 341-344.</mixed-citation></ref><ref id="hanspub.38155-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y.F., Yu, Q., Yu, W.L., et al. (2011) Mycophenolate Mofetil versus Cyclophosphamide in Induction Therapy for Lupus Nephritis: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 11, 826-834.</mixed-citation></ref><ref id="hanspub.38155-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">段培, 宋霞. 狼疮肾炎患者妊娠时机的评估[J]. 中华肾脏病杂志, 2019, 35(6): 471-475.</mixed-citation></ref></ref-list></back></article>